Azacitidine and gemtuzumab ozogamicin as post-transplant maintenance therapy for high-risk hematologic malignancies.
Kaito S, Najima Y, Sadato D, Hirama C, Kishida Y, Nagata A, Konishi T, Yamada Y, Kurosawa S, Yoshifuji K, Shirane S, Shingai N, Toya T, Shimizu H, Haraguchi K, Kobayashi T, Harada H, Okuyama Y, Harada Y, Doki N.
Kaito S, et al. Among authors: shirane s.
Bone Marrow Transplant. 2024 Aug;59(8):1169-1175. doi: 10.1038/s41409-024-02311-5. Epub 2024 May 23.
Bone Marrow Transplant. 2024.
PMID: 38783125